Video Experimental Relacionado
Updated: May 10, 2026
11:20
An Integrated System to Remotely Trigger Intracellular Signal Transduction by Upconversion Nanoparticle-mediated Kinase Photoactivation
Published on: August 30, 2017
6.8K
Un neosubstrato que amplifica la actividad catalítica de la quinasa PINK1 relacionada con la enfermedad de Parkinson
Nicholas T Hertz1, Amandine Berthet, Martin L Sos
1Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA.
Cell
|August 20, 2013
Resumen
Los investigadores descubrieron una nueva forma de aumentar la actividad de PINK1, una proteína clave en la patogénesis de la enfermedad de Parkinson (EP). Este nuevo enfoque de neosubstrato que utiliza trifosfato de kinetina (KTP) ofrece una estrategia terapéutica potencial para la EP.
Área de la Ciencia:
- La bioquímica es la bioquímica.
- La neurociencia es la neurociencia.
- Biología mitocondrial Biología mitocondrial
Sus antecedentes:
- Las mitocondrias juegan un papel crucial en la patogénesis de la enfermedad de Parkinson (EP).
- Las mutaciones en el gen PTEN-inducida por la quinasa 1 (PINK1) están vinculadas a la aparición temprana de la enfermedad de Parkinson y la disfunción mitocondrial.
- Las estrategias terapéuticas actuales para la EP no han explorado la mejora de la actividad de PINK1 debido a la ausencia de sitios reguladores alostéricos conocidos.
Objetivo del estudio:
- Investigar una nueva estrategia terapéutica para la enfermedad de Parkinson mediante la mejora de la actividad de la quinasa PINK1.
- Explorar el potencial de un enfoque de neosubstrato para modular la actividad de PINK1, incluidos los mutantes relacionados con la EP.
Principales métodos:
- Utilizó el análogo de ATP trifosfato de cinetina (KTP) como un neo-sustrato para modular la actividad de PINK1.
- Se evaluó el impacto de KTP y su precursor, la cinetina, en la actividad de PINK1 en modelos celulares.
- Efectos posteriores cuantificados que incluyen el reclutamiento de Parkin, la motilidad mitocondrial y los niveles de apoptosis.
Principales resultados:
- El trifosfato de cinetina (KTP) aumentó con éxito la actividad tanto del tipo salvaje (WT) como del mutante (G309D) PINK1.1.
- La aplicación de kinetin a las células condujo a aumentos significativos en la actividad de PINK1.
- Se observaron resultados biológicamente relevantes, incluido un mejor reclutamiento de Parkin a las mitocondrias despolarizadas, una reducción de la motilidad mitocondrial axonal y una disminución de la apoptosis.
Conclusiones:
- El enfoque de neosubstrato representa una estrategia viable para aumentar la actividad de la quinasa PINK1.
- La cinetina y la KTP demuestran potencial como agentes terapéuticos para afecciones que involucran disfunción de PINK1, como la enfermedad de Parkinson.
- El descubrimiento de neosubstratos abre nuevas vías para regular la actividad de las kinasas en diversos contextos biológicos.
Más Videos Relacionados
Videos de Conceptos Relacionados
01:22Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:25cAMP-dependent Protein Kinase Pathways
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...